Boron Neutron Capture-Enhanced Fast Neutron Therapy (BNC/FNT) for Non-Small Cell Lung Cancer in Canine Patients
The clinical utility of boron neutron capture (BNC) with thermal/epithermal neutron beams has been limited to tumors located at shallow depths, such as in the brain and skin. Capture of the thermal neutron component within a predominantly fast neutron (FN) beam could selectively enhance cytotoxicity in deeply located tumors, such as lung cancer, thereby increasing the availability of this treatment to far greater numbers of cancer patients.1, 2, 3, 4 Even combining concurrent chemotherapy and photon radiation followed by surgery for treatment of locally advanced non-small cell lung cancer (NSCLC), local recurrence was detected in 40% of treatment failures.5 With improved effectiveness of systemic therapies, local control of bulky disease at the primary site becomes increasingly important for improving median survival and increasing probability of cure. The purpose of this ongoing study was to determine the feasibility and toxicity of BNC/FNT in a trial for dogs with spontaneous NSCLC.
KeywordsToxicity Boron Beryllium Esophagitis Disodium
Unable to display preview. Download preview PDF.
- 1.G.E. Laramore, P. Wooton, J.C. Livesey, D.S. Wilbur, R. Risler, M. Phillips, J. Jacky, T.A. Buchholz, T.W. Griffin, and S. Brossard. Boron neutron capture therapy: a mechanism for achieving a concomitant tumor boost in fast neutron radiotherapy, Int. J. Radiat. Oncol. Biol. Phys., 5:1135–1142, 1994.CrossRefGoogle Scholar
- 2.W.-J. Koh, J.M. Krall, L.J. Peters, M.H. Maor, G.E. Laramore, C.M. Burnison, L.W. Davis, S. Zink, and T.W. Griffin. Neutron vs photon radiation therapy for inoperable regional non-small cell lung cancer: results of a multicenter randomized trial, Int. J. Radiat. Oncol. Biol. Phys., 27:499–505, 1993.PubMedCrossRefGoogle Scholar
- 3.G.E. Laramore, and K.J. Stelzer. Neutron capture therapy (NCT) enhancement of fast neutron radiotherapy: past, present, and future directions,in “Frontiers in Neutron Capture Therapy,” M.F. Hawthorne, K. Shelly, R.W. Wiersema, eds., Kluwer Academic/Plenum Publishers, New York, 2001, pp. 695–702.CrossRefGoogle Scholar
- 5.K.S. Albain, V.W. Rusch, J.J. Crowley, T.W. Rice, A.T. Turrisi, J.K. Weick, V.A. Lonchyna, C.A. Presant, R.J. McKenna, D.R. Gandara, H. Fosmire, S.A. Taylor, K.J. Stelzer, K.R. Beasly, and R.B. Livingston. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805, J. Clin. Oncol., 13:1180–1892, 1995.Google Scholar